Grace Therapeutics, Inc. (GRCE)

Grace Therapeutics Income Statement

Financials in millions USD. Fiscal year is April - March.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec 31, 2025	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022	Mar 31, 2021
Revenue	-	-	-	-	-	0.2
Cost of Revenue	-	-	-	-	-	0.08
Gross Profit	-	-	-	-	-	0.12
Selling, General & Admin	7.63	7.17	6.68	8.28	6.58	6.66
Research & Development	3.62	9.51	4.59	9.93	5.56	4.17
Operating Expenses	11.25	16.68	11.28	18.21	12.14	10.84
Operating Income	-11.25	-16.68	-11.28	-18.21	-12.14	-10.72
Interest Expense	-	-	-	-	-	-0.26
Interest & Investment Income	0.71	0.71	0.91	0.25	0.08	0.11
Currency Exchange Gain (Loss)	-0	-0.02	-0.02	-0.07	-0.3	-0.68
Other Non Operating Income (Expenses)	3.54	3.22	-2.73	0.01	5.34	-2.43
EBT Excluding Unusual Items	-7	-12.77	-13.11	-18.02	-7.02	-13.98
Merger & Restructuring Charges	-	-	-1.49	-33.51	-3.2	-
Asset Writedown	-0	-0	-0.09	-0.44	-0.25	-5.7
Pretax Income	-7	-12.77	-14.69	-51.97	-10.47	-19.68
Income Tax Expense	-1.02	-3.2	-1.83	-9.54	-0.65	-
Net Income	-5.98	-9.57	-12.85	-42.43	-9.82	-19.68
Net Income to Common	-5.98	-9.57	-12.85	-42.43	-9.82	-19.68
Shares Outstanding (Basic)	16	12	10	7	6	2
Shares Outstanding (Diluted)	16	12	10	7	6	2
Shares Change (YoY)	36.09%	26.85%	28.16%	21.09%	148.46%	40.25%
EPS (Basic)	-0.38	-0.79	-1.35	-5.71	-1.60	-7.96
EPS (Diluted)	-0.38	-0.79	-1.35	-5.71	-1.60	-7.96
Free Cash Flow	-10.13	-14.9	-12.36	-15.93	-17.23	-14.39
Free Cash Flow Per Share	-0.65	-1.23	-1.30	-2.14	-2.81	-5.82
Gross Margin	-	-	-	-	-	61.22%
Operating Margin	-	-	-	-	-	-5467.35%
Profit Margin	-	-	-	-	-	-10039.80%
Free Cash Flow Margin	-	-	-	-	-	-7340.82%
EBITDA	-11.24	-16.67	-11.27	-18.08	-11.22	-9.79
D&A For EBITDA	0.01	0.01	0.01	0.12	0.92	0.92
EBIT	-11.25	-16.68	-11.28	-18.21	-12.14	-10.72

Updated Dec 31, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q